These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 15041274)

  • 61. Monitoring Unfractionated Heparin (UFH) therapy: which Anti-Factor Xa assay is appropriate?
    Ignjatovic V; Summerhayes R; Gan A; Than J; Chan A; Cochrane A; Bennett M; Horton S; Shann F; Lane G; Ross-Smith M; Monagle P
    Thromb Res; 2007; 120(3):347-51. PubMed ID: 17118432
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Comparison of anti-Xa levels in obese and non-obese pediatric patients receiving treatment doses of enoxaparin.
    Richard AA; Kim S; Moffett BS; Bomgaars L; Mahoney D; Yee DL
    J Pediatr; 2013 Feb; 162(2):293-6. PubMed ID: 22959138
    [TBL] [Abstract][Full Text] [Related]  

  • 63. [Anti-factor Xa activity of enoxaparin for thromboprophylaxis in nonsurgical patients is dependent on body mass].
    Jiménez D; Díaz G; Iglesias A; César J; García-Avello A; Martí D; Escobar C; Vidal R; Sueiro A
    Arch Bronconeumol; 2008 Dec; 44(12):660-3. PubMed ID: 19091234
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Thrombotic reactant markers in non-ST segment elevation acute coronary syndromes treated with either enoxaparin (low molecular weight heparin) or unfractionated heparin.
    Gurfinkel E; Duronto E; Colorio C; Bozovich G; Cohen M; Mautner B
    J Thromb Thrombolysis; 1999 Oct; 8(3):227-32. PubMed ID: 10500313
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Anti-Xa stability of diluted enoxaparin for use in pediatrics.
    Dager WE; Gosselin RC; King JH; Christensen CL; Owings JT; Larkin EC
    Ann Pharmacother; 2004 Apr; 38(4):569-73. PubMed ID: 14982984
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Subcutaneous enoxaparin with early invasive strategy in patients with acute coronary syndromes.
    Collet JP; Montalescot G; Golmard JL; Tanguy ML; Ankri A; Choussat R; Beygui F; Drobinski G; Vignolles N; Thomas D
    Am Heart J; 2004 Apr; 147(4):655-61. PubMed ID: 15077081
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Dosing strategy in patients with renal failure receiving enoxaparin for the treatment of non-ST-segment elevation acute coronary syndrome.
    Hulot JS; Montalescot G; Lechat P; Collet JP; Ankri A; Urien S
    Clin Pharmacol Ther; 2005 Jun; 77(6):542-52. PubMed ID: 15961985
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Peak plasma anti-Xa levels after first and third doses of enoxaparin in women receiving weight-based thromboprophylaxis following caesarean section: a prospective cohort study.
    Hiscock RJ; Casey E; Simmons SW; Walker SP; Newell PA
    Int J Obstet Anesth; 2013 Nov; 22(4):280-8. PubMed ID: 23958275
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients With Acute Symptomatic Deep-Vein Thrombosis) study.
    Agnelli G; Gallus A; Goldhaber SZ; Haas S; Huisman MV; Hull RD; Kakkar AK; Misselwitz F; Schellong S;
    Circulation; 2007 Jul; 116(2):180-7. PubMed ID: 17576867
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Elevated activated partial thromboplastin time does not correlate with heparin rebound following cardiac surgery.
    Taneja R; Marwaha G; Sinha P; Quantz M; Stitt L; Gao R; Subramanian S; Schaus M; Keeney M; Chin-Yee I; Murkin J
    Can J Anaesth; 2009 Jul; 56(7):489-96. PubMed ID: 19408066
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Potent arterial antithrombotic effect of direct factor-Xa inhibition with ZK-807834 administered to coronary artery disease patients.
    Zafar MU; Farkouh ME; Osende J; Shimbo D; Palencia S; Crook J; Leadley R; Fuster V; Chesebro JH
    Thromb Haemost; 2007 Mar; 97(3):487-92. PubMed ID: 17334518
    [TBL] [Abstract][Full Text] [Related]  

  • 72. [Monitoring of plasma concentration of low molecular weight heparin--comparative evaluation with chromogenic and clotting assays].
    Katagiri H; Itoh S; Uchida T; Kawai Y; Watanabe K
    Rinsho Byori; 1999 Nov; 47(11):1046-51. PubMed ID: 10590682
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Monitoring unfractionated heparin therapy: relationship between eight anti-Xa assays and a protamine titration assay.
    Kitchen S; Theaker J; Preston FE
    Blood Coagul Fibrinolysis; 2000 Mar; 11(2):137-44. PubMed ID: 10759006
    [TBL] [Abstract][Full Text] [Related]  

  • 74. A microfluidic anti-Factor Xa assay device for point of care monitoring of anticoagulation therapy.
    Harris LF; Rainey P; Castro-López V; O'Donnell JS; Killard AJ
    Analyst; 2013 Sep; 138(17):4769-76. PubMed ID: 23666610
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Noncitrated whole blood is optimal for evaluation of postinjury coagulopathy with point-of-care rapid thrombelastography.
    Kashuk JL; Moore EE; Le T; Lawrence J; Pezold M; Johnson JL; Cothren CC; Biffl WL; Barnett C; Sabel A
    J Surg Res; 2009 Sep; 156(1):133-8. PubMed ID: 19577246
    [TBL] [Abstract][Full Text] [Related]  

  • 76. FXa inhibition and coagulation changes during DVT prophylaxis by enoxaparin over the course of a 15-day follow-up in septic patients.
    Zenáhlíková Z; Kvasnicka J; Kudrnová Z; Sudrová M; Brzezková R; Mazoch J; Malíková I; Vyborny J; Erhart D; Pecen L
    Clin Appl Thromb Hemost; 2010 Oct; 16(5):584-90. PubMed ID: 19850587
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Fluctuations of anti-Xa concentrations during maintenance enoxaparin therapy for neonatal thrombosis.
    Lulic-Botica M; Rajpurkar M; Sabo C; Tutag-Lehr V; Natarajan G
    Acta Paediatr; 2012 Apr; 101(4):e147-50. PubMed ID: 22211705
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Dalteparin thromboprophylaxis for critically ill medical-surgical patients with renal insufficiency.
    Rabbat CG; Cook DJ; Crowther MA; McDonald E; Clarke F; Meade MO; Lee KA; Cook RJ
    J Crit Care; 2005 Dec; 20(4):357-63. PubMed ID: 16310608
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Biomarkers and coagulation tests for assessing the biosimilarity of a generic low-molecular-weight heparin: results of a study in healthy subjects with enoxaparin.
    Kuczka K; Harder S; Picard-Willems B; Warnke A; Donath F; Bianchini P; Parma B; Blume H
    J Clin Pharmacol; 2008 Oct; 48(10):1189-96. PubMed ID: 18716314
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Monitoring of heparin and low molecular weight heparin with capillary and venous whole blood.
    Harenberg J; Giese C; Dempfle CE; Stehle G; Heene DL
    Thromb Haemost; 1988 Dec; 60(3):377-81. PubMed ID: 2853458
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.